Your session is about to expire
← Back to Search
Ritlecitinib for Scarring Alopecia
Study Summary
This trial will administer a new drug to alopecia patients in order to improve hair loss. The goal is to also understand these diseases better.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 460 Patients • NCT04413617Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken part in any drug trials within the last 4 weeks or 5 half-lives of the drug.I have had alopecia for over 7 years, have severe scarring, or am losing hair very quickly.I do not have active hepatitis B, C, or HIV.I have had central centrifugal cicatricial alopecia for at least 6 months.I am not pregnant or breastfeeding, and if able to have children, I use effective birth control and have negative pregnancy tests.I have no current cancers except for treated skin cancer or cervical pre-cancer.You've had a test for tuberculosis that came back negative in the past year.My hair loss cause is unknown or due to multiple factors like pregnancy, medication, or hormonal changes.I am in good health overall, as confirmed by recent medical exams and tests.I haven't taken antibiotics or antivirals for infections in the last 4 weeks.I need surgery soon or have it scheduled during the study period.You have answered "yes" to questions 4 and/or 5 on a suicide rating scale at the second visit.I do not have any scalp conditions like psoriasis or dermatitis.I do not have any diseases like lupus or thyroid issues that cause hair loss.I have a history of large, raised scars on my scalp.I have not had major surgery or significant trauma in the last month.I haven't had a serious infection requiring hospital stay or IV antibiotics in the last 6 months.I am 18 years old or older.I have a history of diseases related to lymph nodes or blood cancer.I have had blood clots or inherited blood clotting disorders.You have certain abnormal results in your blood tests, kidney function, liver function, or ECG, or have certain medical conditions that may affect your safety or the study results. This includes specific blood cell counts, kidney function, liver function, recent vaccinations, recent use of certain medications, history of certain diseases, and abnormal ECG results.I have had a severe or repeated herpes infection.
- Group 1: PF-06651600 (Ritlecitinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are we aiming to learn from this research?
"The primary objective of this clinical trial is to measure the severity of treatment-emergent adverse events over a period of 48 weeks. Secondary objectives include measuring the lichen planopilaris activity index, changes in mRNA levels of CXCR3, and change in Ct values of mRNA levels of CXCR3 at baseline and week 24."
What has been the most serious outcome for patients using PF-06651600?
"PF-06651600 is still being studied in Phase 2 clinical trials, so there is not yet any data supporting its efficacy. However, there is some evidence that suggests it may be safe, and it received a score of 2."
Are patients still being sought for this research?
"The clinical trial in question is not presently recruiting patients, as stated on the website clinicaltrials.gov. This particular study was first posted on September 1st, 2022 and was most recently edited on September 19th, 2022. Although this one trial has completed recruitment, there are many other medical studies currently looking for patients to participate."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger